{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Parsippany",
      "state": "NJ",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "74702",
      "recalling_firm": "Actavis Inc",
      "address_1": "400 Interpace Pkwy",
      "address_2": "N/A",
      "postal_code": "07054-1120",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide",
      "recall_number": "D-1457-2016",
      "product_description": "Glipizide 2.5 mg Extended-release tablets, 30-count bottle, Rx Only, Manufactured By: Patheon Pharmaceuticals Inc Cincinnati, OH  45237, NDC 00591-0900-30",
      "product_quantity": "167,152 bottles",
      "reason_for_recall": "Failed Dissolution Specifications: Glipizide 2.5 mg ER  Tablets exceeded  dissolution specification rates for the 10 hour testing point.",
      "recall_initiation_date": "20160630",
      "center_classification_date": "20160815",
      "termination_date": "20170703",
      "report_date": "20160824",
      "code_info": "Lot # 3132593, 3132594, 3134420, 3134421,3134422, Exp. 02/17"
    }
  ]
}